Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wen Wan

Showing results (321-330 of 327) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 327 results.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2017
Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue InfectionShu-Wen Wan, Pei-Wei Chen, Chin-Yu Chen, et al.
BMC Biology|August 20, 2025
Genomic formation of lower Yellow River populations in the Han dynastyZhi Ji, Kui Chen, Jiajing Zheng, et al.
Plos Pathogens|April 29, 2022
Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse modelSen-Mao Tien, Po-Chun Chang, Yen-Chung Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
The New England Journal of Medicine|October 14, 2011
Oral acyclovir suppression and neurodevelopment after neonatal herpesDavid W Kimberlin, Richard J Whitley, Wen Wan, et al.
Pageof 33

Showing results (321-330 of 327) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 327 results.
The Journal of Infectious Diseases|December 12, 2012
Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin, Edward P Acosta, Mark N Prichard, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 15, 2017
Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue InfectionShu-Wen Wan, Pei-Wei Chen, Chin-Yu Chen, et al.
BMC Biology|August 20, 2025
Genomic formation of lower Yellow River populations in the Han dynastyZhi Ji, Kui Chen, Jiajing Zheng, et al.
Plos Pathogens|April 29, 2022
Therapeutic efficacy of humanized monoclonal antibodies targeting dengue virus nonstructural protein 1 in the mouse modelSen-Mao Tien, Po-Chun Chang, Yen-Chung Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple MyelomaBeata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
The New England Journal of Medicine|October 14, 2011
Oral acyclovir suppression and neurodevelopment after neonatal herpesDavid W Kimberlin, Richard J Whitley, Wen Wan, et al.
Pageof 33